Yousef a postdoctoral scientist at the Toronto Kallikrein
In cancer, by the end of our fiscal year we expect to launch our second kallikrein
assay for ovarian cancer research purposes.
To this end, future studies should examine the combined prognostic value of hK7 with other kallikreins
, as well as nonkallikrein prognostic biomarkers, in ovarian cancer.
In this preliminary study using an aggressive ovarian cell line transfected with one or more kallikreins
, nude mice treated with two kallikrein
-transfected cells lines (IBT-02-23 and IBT-02-20/21) showed significantly longer survival times compared to controls.
studied to date are known to be up- or down-regulated at the mRNA and/or protein level in breast, prostate, ovarian, and testicular cancers (2).
With regards to the therapeutics, IBEX has completed the initial evaluation of its kallikreins
in in vitro models with very encouraging results and plans to enter into in vivo proof of concept studies later this year.
The potential significance of the other kallikreins
in tumor biology has been reviewed (1, 4-6, 8).
I am also pleased to report that subsequent to the end of our first quarter, Nature Reviews Cancer published a scientific paper entitled "The Emerging Roles of Human Tissue Kallikreins
in Cancer co-authored by Carla Borgono and, Dr.
TSX:IBT), a Montreal-based biopharmaceutical company, today announced the publication of a scientific paper in the November 2004 issue of Nature Reviews Cancer entitled "The Emerging Roles of Human Tissue Kallikreins
in Cancer" and co-authored by IBEX's lead clinical investigator, Dr.
Human stratum corneum chymotryptic enzyme (hK7; HSCCE) (9,10), one of the few tissue kallikreins
for which a physiologic function has been proposed, catalyzes the degradation of intercellular cohesive structures in the outermost layer of the skin and contributes to the cell shedding process at the skin surface (11).
IBEX's cancer research program is focused on exploring the role of kallikreins
in neoplastic diseases, with the goal of discovering new and improved treatment for ovarian and prostate cancer.
Although this study demonstrated absence of cross-reactivity to other kallikreins
, it could not exclude the possibility that poor detection of immunoreactive hK4 may have been attributable to low efficiency of the assay for recognizing hK4 in its native conformation and/or inefficient or absent hK4 translation and secretion.